Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 14.79
+0.05 (0.34%)
Feb 3, 2026, 9:55 AM CST
SHA:600535 Revenue
Tasly Pharmaceutical Group had revenue of 2.02B CNY in the quarter ending September 30, 2025, a decrease of -3.27%. This brings the company's revenue in the last twelve months to 8.35B, down -2.56% year-over-year. In the year 2024, Tasly Pharmaceutical Group had annual revenue of 8.50B, down -2.03%.
Revenue (ttm)
8.35B
Revenue Growth
-2.56%
P/S Ratio
2.64
Revenue / Employee
761.66K
Employees
10,958
Market Cap
22.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.50B | -175.87M | -2.03% |
| Dec 31, 2023 | 8.67B | 36.58M | 0.42% |
| Dec 31, 2022 | 8.64B | 685.47M | 8.62% |
| Dec 31, 2021 | 7.95B | -5.62B | -41.43% |
| Dec 31, 2020 | 13.58B | -5.42B | -28.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 15.20B |
| China Resources Double-Crane Pharmaceutical | 10.95B |
| Apeloa Pharmaceutical Co.,Ltd | 10.50B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.02B |
| Kangmei Pharmaceutical | 5.28B |
| Betta Pharmaceuticals | 3.26B |